REGN Stock Overview
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide.
Snowflake Score | |
---|---|
Valuation | 4/6 |
Future Growth | 3/6 |
Past Performance | 2/6 |
Financial Health | 5/6 |
Dividends | 0/6 |
Regeneron Pharmaceuticals, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$853.60 |
52 Week High | US$913.50 |
52 Week Low | US$630.50 |
Beta | 0.14 |
1 Month Change | -3.82% |
3 Month Change | -2.50% |
1 Year Change | 20.65% |
3 Year Change | 110.53% |
5 Year Change | 181.25% |
Change since IPO | 108.79% |
Recent News & Updates
Recent updates
Shareholder Returns
REGN | AT Biotechs | AT Market | |
---|---|---|---|
7D | 0.4% | 0.2% | 1.6% |
1Y | 20.7% | -11.3% | 3.7% |
Return vs Industry: REGN exceeded the Austrian Biotechs industry which returned -12.9% over the past year.
Return vs Market: REGN exceeded the Austrian Market which returned 3.5% over the past year.
Price Volatility
REGN volatility | |
---|---|
REGN Average Weekly Movement | 2.1% |
Biotechs Industry Average Movement | 7.2% |
Market Average Movement | 3.3% |
10% most volatile stocks in AT Market | 5.2% |
10% least volatile stocks in AT Market | 1.6% |
Stable Share Price: REGN has not had significant price volatility in the past 3 months.
Volatility Over Time: REGN's weekly volatility (2%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1988 | 13,450 | Leonard Schleifer | www.regeneron.com |
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company’s products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults.
Regeneron Pharmaceuticals, Inc. Fundamentals Summary
REGN fundamental statistics | |
---|---|
Market cap | €91.11b |
Earnings (TTM) | €3.69b |
Revenue (TTM) | €12.26b |
24.6x
P/E Ratio7.4x
P/S RatioIs REGN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
REGN income statement (TTM) | |
---|---|
Revenue | US$13.12b |
Cost of Revenue | US$6.25b |
Gross Profit | US$6.86b |
Other Expenses | US$2.91b |
Earnings | US$3.95b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 02, 2024
Earnings per share (EPS) | 36.79 |
Gross Margin | 52.32% |
Net Profit Margin | 30.14% |
Debt/Equity Ratio | 7.6% |
How did REGN perform over the long term?
See historical performance and comparison